期刊文献+

中国生物样本库资源管理与应用现状分析 被引量:12

Analysis of current situation of management and application of Biobank in China
暂未订购
导出
摘要 目的通过对调研数据的统计分析,了解我国生物样本库的现状,从宏观层面掌握生物样本库的发展方向,整合国内样本库资源,推进我国生物样本库标准化建设。方法针对全国生物样本库发起调研,从生物样本库资金支持、组织人员、场地环境及设施设备、信息化管理系统、流程管理、质量管理等6个方面50项内容开展了调研。结果参与本次调研的单位类型主要有大学、国有企业、科研院所、内资企业和医疗机构,其中医疗机构占92%。结论各地区生物样本库发展不均衡,各医院在资金投入、场地环境配置、组织人员安排等都存在较大差异,我国生物样本库的标准化建设任重而道远。 Objective To understand the status of China's biobank through statistical analysis of data from investigation, to grasp the direction of development biobank in macro level, to integrate the resources of domestic biobank and to standardize biobank construction in China. Methods Carry out an investigation for 50 items in 6 aspects of biobank all over the country. The 6 aspects were financial support,organization personnel, environment and facilities, information management system, process management and quality management. Results The types of organizations involved in this research are mainly state-owned enterprises, universities, research institutes, enterprises and medical institutions. The medical institutions accounted for 92%. Conclusion Biobank developments are uneven in different regions. There are great differences between different biobanks such as capital investment, environment configuration and personnel arrangement. There will be a long way to go for the construction of standard China's biobank.
出处 《实用器官移植电子杂志》 2017年第6期448-451,共4页 Practical Journal of Organ Transplantation(Electronic Version)
基金 国家重点研发计划国家质量基础的共性技术研究与应用专项(2016YFF02023) 国家人类遗传资源共享服务平台上海创新中心建设项目(2005DKA21300) 国家重点研发计划"精准医学研究"重点项目(2017YFC0908300 2017YFC0908403)
关键词 生物样本库 生物样本 调研 Biobank Bio-material Investigation
  • 相关文献

参考文献9

二级参考文献80

  • 1陈仕林,程子敏.检验质量中不容忽视的分析前因素[J].检验医学与临床,2005,2(1):32-33. 被引量:7
  • 2季加孚.北京大学临床肿瘤学院标本库的建设[J].北京大学学报(医学版),2005,37(3):329-330. 被引量:81
  • 3孙磊.美国组织库事业发展情况[J].中国修复重建外科杂志,2006,20(11):1145-1146. 被引量:13
  • 4方福德.与肿瘤个体化诊疗相关的科技计划[J].中华肿瘤杂志,2006,28(10):798-798. 被引量:6
  • 5US Department of Health and Human Services, Food and Drug Administration. Challenge and opportunity on the critical path to new medical products [ EB/OL]. (2004-03-16). http://www. fda. gov/ScienceResearch/SpecialTopics/CriticalPathIntiative/Cri- ticalPathOpportunitiesReports/. UCM0771262. htm.
  • 6US Department of Health and Human Services, Food and Drug Administration. Critical path opportunities report [ EB/OL ]. (2006-03). http ://www. fda. gov/ScienceResearch/SpecialTopics/ CriticalPathIntiative/CriticalPathOpportunitiesReports/. UCM077- 254. pdf.
  • 7Vaught J, Rogers J, Myers K, et al. An NCI perspective on creating sustainable biospecimen resources. J Natl Cancer Inst Monogr, 2011,42:1-7.
  • 8Vgv6ri , Welinder C, Lindberg H, et al. Biobank resources for future patient care:developments, principles and concepts. J Clin Bioinforma, 2011,1:24.
  • 9Merrero JA, Henley KS. The role of serum biomarkers in hepatocellular carcinoma surveillance. Gastroenterol Hepatol, 2011,7:821-823.
  • 10Franco JR, Simarro PP, Diarra A, et al. The human African trypanosomiasis specimen biobank: a necessary tool to support research of new diagnostics. PLoS Negl Trop Dis, 2012,6:e1571.

共引文献174

同被引文献111

引证文献12

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部